• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/19/26 4:12:43 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    Alumis Inc._March 19, 2026
    0001847367false00018473672026-03-192026-03-19

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 19, 2026

    Alumis Inc.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

      ​ ​ ​

    001-42143

      ​ ​ ​

    86-1771129

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    280 East Grand Avenue

    South San Francisco, California 94080

    (Address of principal executive offices)

    Registrant’s telephone number, including area code: (650) 231-6625

    N/A

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

      ​ ​ ​

    Trading
    Symbol(s)

      ​ ​ ​

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share

     

    ALMS

     

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    ​

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    On March 19, 2026, Alumis Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

    All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d)Exhibits.

    ​

    Exhibit No.

      ​ ​ ​

    Description

    99.1

    Press Release, dated March 19, 2026.

    104

      ​

    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    Alumis Inc.

    ​

    ​

    ​

    By:

    /s/ Martin Babler

    ​

    ​

    Martin Babler

    ​

    ​

    President and Chief Executive Officer

    ​

    Dated: March 19, 2026

    ​

    Get the next $ALMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    3/11/2026$46.00Strong Buy
    Raymond James
    2/25/2026$44.00Buy
    Stifel
    1/21/2026$37.00Buy
    Chardan Capital Markets
    7/25/2025$17.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    More analyst ratings

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

    – Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma com

    3/19/26 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

    – Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe pl

    3/18/26 8:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis to Present at the Leerink Partners Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next

    3/2/26 8:05:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $9,999,995 worth of shares (588,235 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/13/26 6:20:06 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Labs, Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:59:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Capital Management Vi Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:58:40 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Alumis with a new price target

    Raymond James initiated coverage of Alumis with a rating of Strong Buy and set a new price target of $46.00

    3/11/26 8:36:17 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Alumis with a new price target

    Stifel initiated coverage of Alumis with a rating of Buy and set a new price target of $44.00

    2/25/26 7:48:26 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Alumis with a new price target

    Chardan Capital Markets initiated coverage of Alumis with a rating of Buy and set a new price target of $37.00

    1/21/26 8:54:19 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    SEC Filings

    View All

    SEC Form S-3ASR filed by Alumis Inc.

    S-3ASR - ALUMIS INC. (0001847367) (Filer)

    3/19/26 5:02:31 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Alumis Inc.

    10-K - ALUMIS INC. (0001847367) (Filer)

    3/19/26 4:23:01 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALUMIS INC. (0001847367) (Filer)

    3/19/26 4:12:43 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Goldstein David M transferred by will 1,000 shares) (SEC Form 5)

    5 - ALUMIS INC. (0001847367) (Issuer)

    2/11/26 4:10:18 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Legal Officer Pangali Sanam

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/28/26 7:22:01 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President, CEO and Chairman Babler Martin

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/28/26 7:21:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Financials

    Live finance-specific insights

    View All

    Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

    – Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe pl

    3/18/26 8:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

    – Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

    1/6/26 7:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

    – Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Conference Call and Webcast DetailsAlumis' conference call and webcast to

    1/5/26 5:00:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    8/27/24 4:20:38 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alumis Inc.

    SC 13G - ALUMIS INC. (0001847367) (Subject)

    7/11/24 4:30:21 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    7/5/24 9:30:17 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care